SPONSOR
Hoffmann-La Roche
Total Trials
7
Recruiting
7
Phases
Phase 3, Phase 2, Phase 1
Conditions studied: Von Willebrand Disease, Type 3Metastatic Castration-Resistant Prostate CancerRenal ImpairmentEarly-stage HER2+ Breast CancerNeovascular Age-related Macular DegenerationMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Von Willebrand Disease, Type 3, Metastatic Castration-Resistant Prostate Cancer, Renal Impairment, Early-stage HER2+ Breast Cancer.
The trial portfolio spans Phase 3, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hoffmann-La Roche
How many clinical trials has Hoffmann-La Roche sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Hoffmann-La Roche, of which 7 are actively recruiting participants. These trials cover conditions including Von Willebrand Disease, Type 3, Metastatic Castration-Resistant Prostate Cancer, Renal Impairment. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hoffmann-La Roche research focus on?
Hoffmann-La Roche clinical trials span Von Willebrand Disease, Type 3, Metastatic Castration-Resistant Prostate Cancer, Renal Impairment, Early-stage HER2+ Breast Cancer, Neovascular Age-related Macular Degeneration, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hoffmann-La Roche clinical trial?
To participate in a Hoffmann-La Roche trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hoffmann-La Roche trials with current recruitment status updated daily.
Clinical Trials by Hoffmann-La Roche
NCT06998524 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
NCT07287150 Phase 2
Recruiting
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
NCT07741604 Phase 1
Recruiting
A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions
Renal Impairment
NCT07527741
Recruiting
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
Early-stage HER2+ Breast Cancer
NCT06847542 Phase 3
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
NCT06419374 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
NCT05091424 Phase 1
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology